VYNE Q1 2022 Earnings Report
Key Takeaways
VYNE Therapeutics reported financial results for Q1 2022, highlighting progress with FMX114 and VYN201. The company reported positive Phase 1b data for FMX114 and promising preclinical data for VYN201. They also completed the divestiture of their topical minocycline franchise.
Reported positive Phase 1b safety and efficacy data for FMX114 in mild-to-moderate atopic dermatitis.
Released promising preclinical data for VYN201.
Completed the divestiture of the topical minocycline franchise.
Anticipates cash, cash equivalents and restricted cash as of March 31, 2022 will be sufficient to fund its operations through at least the first quarter of 2023.
VYNE
VYNE
Forward Guidance
VYNE anticipates that its cash, cash equivalents and restricted cash as of March 31, 2022 will be sufficient to fund its operations through at least the first quarter of 2023.